It is the mitochondrial pyruvate transporter inhibitor MSDC-0602 K (MSDC). The finding is the result of a study conducted by researchers at the University of Virginia Health (UVA), led by the Dr. Jie Sun, which has just been published in the journal “Science Immunology”.
In it study they affirm that heThe relationship between diabetes and Covid is two-way: while people with diabetes and high blood glucose (hyperglycemia) are predisposed to severe Covid, SARS-CoV-2 infection can also cause hyperglycemia and exacerbate the underlying metabolic syndrome .
“Interventions capable of breaking the web of SARS-CoV-2 infection, hyperglycemia and hyperinflammation, all factors driving the pathophysiology of Covid, are urgently needed. Here we show that genetic ablation or pharmacological inhibition of the mitochondrial pyruvate carrier ( MPC) attenuates severe illness after influenza or pneumonia “caused by this virus,” they explain.
In their assay MPC inhibition using a second generation insulin sensitizer, MSDC-0602K (MSDC) dampened lung inflammation and promoted lung recovery. At the same time, it reduced blood glucose levels and hyperlipidemia after viral pneumonia in obese mice. Mechanistically, MPC inhibition elicited attenuated virus-induced inflammatory responses.
“MSDC enhanced responses to nirmatrelvir (the antiviral component of Paxlovid) to provide high levels of protection against the development of severe host disease after SARS-CoV-2 infection and suppressed cellular inflammation in autopsied human lungs with Covid , demonstrating its translational potential for the treatment of this virus in severe cases. Taken together, we discovered a metabolic pathway that simultaneously modulates lung inflammation, tissue recovery, and host metabolic health.”